12 Month Price Forecast For LYEL
Distance to LYEL Price Forecasts
LYEL Price Momentum
🤔 Considering Lyell (LYEL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 9:58 AM UTC
LYEL Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, LYEL has a consensus that is neutral. The median price target is $0.80, with forecasts ranging from $0.60 to $1.00. Currently, there are 0 Buy ratings, 3 Hold ratings, and 1 Sell ratings.
With LYEL currently trading at $0.58, the median price forecast suggests a 39.0% upside. The most optimistic forecast comes from Mitchell Kapoor at HC Wainwright & Co., projecting a 73.8% upside, while at provides the most conservative target, suggesting a 4.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LYEL Analyst Consensus
LYEL Price Target Range
Latest LYEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LYEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $1.00 |
| Oct 30, 2024 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $1.00 |
| Oct 28, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $1.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $1.00 |
| Jun 27, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Downgrade | $1.00 |
| Jun 27, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $6.00 |
| May 7, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $6.00 |
| Feb 29, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $6.00 |
| Nov 9, 2023 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $8.00 |
| Aug 28, 2023 | JP Morgan | Eric Joseph | Neutral | Downgrade | $5.00 |
| May 5, 2023 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $9.00 |
| Mar 2, 2023 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $9.00 |
| Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $4.00 |
| Nov 14, 2022 | Morgan Stanley | Matthew Harrison | Equal-Weight | Downgrade | $7.00 |
| Nov 11, 2022 | Goldman Sachs | Salveen Richter | Neutral | Downgrade | $0.00 |
| Oct 17, 2022 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $12.00 |
| May 24, 2022 | Goldman Sachs | Salveen Richter | Buy | Maintains | $12.00 |
| Mar 31, 2022 | Goldman Sachs | Buy | Maintains | $21.00 | |
| Jan 6, 2022 | Morgan Stanley | Overweight | Maintains | $20.00 | |
| Jul 12, 2021 | B of A Securities | Buy | Initiates | $0.00 |
Stocks Similar to Lyell Immunopharma, Inc.
The following stocks are similar to Lyell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lyell Immunopharma, Inc. (LYEL) Financial Data
Lyell Immunopharma, Inc. has a market capitalization of $166.77M with a P/E ratio of -0.6x. The company generates $63,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +36.0% quarter-over-quarter, while maintaining an operating margin of -148,544.1% and return on equity of -33.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Lyell Immunopharma, Inc. (LYEL) Company Overview
About Lyell Immunopharma, Inc.
Develops T cell therapies for solid tumors.
The company focuses on creating advanced therapies through T cell reprogramming technologies, generating revenue by developing and commercializing these innovative treatments. It is currently advancing several product candidates through clinical trials, aiming to address unmet medical needs in oncology.
Lyell Immunopharma, Inc. was founded in 2018 and is based in South San Francisco, California. The company is actively working on multiple Phase 1 clinical trials for its lead candidates LYL797 and LYL845, as well as exploring preclinical options, which positions it for potential growth in the cell therapy market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
224
CEO
Dr. Lynn Seely M.D., Ph.D.
Country
United States
IPO Year
2021
Website
lyell.comLyell Immunopharma, Inc. (LYEL) Latest News & Analysis
Lyell Immunopharma (LYEL) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
Lyell Immunopharma's upgrade to Zacks Rank #1 signals strong earnings potential, boosting investor confidence and likely driving the stock price higher.
Lyell Immunopharma (Nasdaq: LYEL) plans to advance its CAR T-cell therapy, IMPT-314, into pivotal trials for aggressive large B-cell lymphoma, aiming to improve response rates and duration.
Lyell Immunopharma's advancement of IMPT-314 into pivotal trials could signal potential market leadership in CAR T-cell therapies, impacting future revenue and stock performance.
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
24 days agoLyell Immunopharma (LYEL) is now technically oversold, suggesting reduced selling pressure, and analysts are revising earnings estimates higher, indicating a potential trend reversal.
Lyell Immunopharma's oversold status and positive analyst revisions suggest a potential rebound, indicating an opportunity for gains as selling pressure eases.
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
23 days agoLyell Immunopharma (LYEL) is now technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates higher, indicating a potential trend reversal.
Lyell Immunopharma's oversold status and upgraded earnings estimates suggest a possible rebound, signaling an opportunity for investors to capitalize on a potential recovery.
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
1 month agoLyell Immunopharma (LYEL) is currently oversold, suggesting potential for a trend reversal, supported by analysts raising earnings estimates.
Lyell Immunopharma's oversold status and analysts raising earnings estimates suggest potential for a rebound, signaling a favorable entry point for investors.
Lyell Immunopharma (Nasdaq: LYEL) reported positive initial clinical data for its CAR T-cell therapy IMPT-314 in large B-cell lymphoma at the ASH Annual Meeting, advancing its pipeline for hematologic malignancies.
Positive clinical data for Lyell Immunopharma's IMPT-314 could enhance investor confidence, potentially boosting stock value and attracting interest in its CAR T-cell therapy pipeline.
Frequently Asked Questions About LYEL Stock
What is Lyell Immunopharma, Inc.'s (LYEL) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Lyell Immunopharma, Inc. (LYEL) has a median price target of $0.80. The highest price target is $1.00 and the lowest is $0.60.
Is LYEL stock a good investment in 2025?
According to current analyst ratings, LYEL has 0 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $0.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LYEL stock?
Wall Street analysts predict LYEL stock could reach $0.80 in the next 12 months. This represents a 39.0% increase from the current price of $0.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lyell Immunopharma, Inc.'s business model?
The company focuses on creating advanced therapies through T cell reprogramming technologies, generating revenue by developing and commercializing these innovative treatments. It is currently advancing several product candidates through clinical trials, aiming to address unmet medical needs in oncology.
What is the highest forecasted price for LYEL Lyell Immunopharma, Inc.?
The highest price target for LYEL is $1.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 73.8% increase from the current price of $0.58.
What is the lowest forecasted price for LYEL Lyell Immunopharma, Inc.?
The lowest price target for LYEL is $0.60 from at , which represents a 4.3% increase from the current price of $0.58.
What is the overall LYEL consensus from analysts for Lyell Immunopharma, Inc.?
The overall analyst consensus for LYEL is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $0.80.
How accurate are LYEL stock price projections?
Stock price projections, including those for Lyell Immunopharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
